CBL (cannabicyclol) is a rare minor cannabinoid that forms when CBC breaks down under light or heat, and it doesn't intoxicate. Chemistry makes it, rather than a plant enzyme, so it collects in trace amounts as cannabis ages. Few cannabinoids have been studied less.
C21H30O2 · MW ≈ 314.46 · CAS 21366-63-2 · PubChem CID 30607 · tetracyclic · non-intoxicating · forms when CBC degrades under light, UV or heat · trace amounts in aged cannabis · barely studied
Forms from CBC. Nothing on the map forms from it.
40 questions, and 21 of them earn a verified grade on the six-rung evidence ladder. 15 carry an evidence state instead of a rung, and most of those read no primary evidence: our registry has no study on the question, a different finding from not supported and marked differently. The other 4 use an author qualifier still waiting to enter the controlled vocabulary. They appear without a grade chip until it does, rather than wear a guessed one.
Leave cannabis in the light long enough and some of its CBC folds into a new shape, CBL. The chemistry of that fold is clean and well described; what the result does in a body is close to a blank, and our registry holds no verified pharmacology for it. So the verified science is given as fact, with a grade: what CBL is, its formula and CAS number, how light turns CBC into CBL, and why it isn't thought to intoxicate. Statements about effects are reported as claims made by others, with their limits attached; CBG Atlas does not make, adopt, or affirm these claims. Not medical or legal advice.
CBL (cannabicyclol) is a rare minor cannabinoid that forms when CBC breaks down under light or heat, and it doesn't intoxicate. Chemistry makes it, rather than a plant enzyme, so it collects in trace amounts as cannabis ages. Few cannabinoids have been studied less.
Cannabicyclol, a name that describes the structure: a tetracyclic ("cyclo") cannabinoid created when light triggers a ring-closing reaction inside CBC. Formula C21H30O2, molecular weight ≈ 314.46, CAS 21366-63-2, PubChem CID 30607. The chemistry is Established. CBL's biology is not, and it remains catalogue in progress.
Yes. CBL is a photochemical degradation product of CBC: ultraviolet light, with heat as an accomplice, drives a [2+2] ring-closing reaction that turns CBC into CBL over time. The process runs without an enzyme, and CBL builds up as cannabis ages, much as CBN forms from THC.
In a sense. CBL occurs naturally in aged or light-exposed cannabis, but as a breakdown product of CBC rather than something the living plant synthesizes directly. Levels are usually trace, well under 0.1%.
No. CBL is generally considered non-intoxicating, and nothing suggests a THC-like high. That view rests on its structure and on current understanding more than on testing, because its pharmacology has barely been studied.
As far as anyone knows, it isn't psychoactive or intoxicating. Research on CBL's pharmacology is close to empty, so anything said about subtler effects would be speculation, and verified human data point in neither direction. The question is open, and it stays catalogue in progress.
Nobody knows. CBL is one of the least-studied cannabinoids, and CBG Atlas has catalogued no verified pharmacology for it, whether receptor or enzyme activity, in either direction. The gap marks the reach of our catalogue and says nothing against CBL. Catalogue in progress. (Not medical advice.)
Nothing specific has been verified. Some cannabinoids at least have in vitro receptor data; for CBL we have catalogued essentially none. So any "activity" claim you see is unsupported, and nobody has disproven it either. Catalogue in progress. (Not medical advice.)
It depends on where the CBL comes from and where you are, more than on the molecule itself. Where hemp-derived cannabinoids under 0.3% Δ⁹-THC are permitted, CBL generally sits inside that framework; elsewhere it may be restricted. A general snapshot as of 2026-07-11, not legal advice, so check local law.
Generally yes, with one limit that matters. Under the 2018 Farm Bill, hemp-derived CBL in a product at or below 0.3% Δ⁹-THC by dry weight is generally legal federally as a hemp product. The catch is the FDA, which has not authorised cannabinoids as foods or dietary supplements, and being a lawful hemp derivative doesn't make CBL a lawful food ingredient. Anyone putting it in a gummy or a capsule meets that wall first. Dated 2026-07-11; general information, not legal advice.
That turns on your state's own law. State laws vary, and some restrict hemp cannabinoids more tightly than federal law does. Statutes rarely name CBL at all, so it usually falls under the state's general hemp and THC rules. Check the current statute or ask a qualified attorney. Dated 2026-07-11; informational only, not legal advice.
Generally not as a freely sold food or supplement. The EU and UK treat extracted cannabinoids as novel foods that need authorisation, and CBL holds none of its own. Canada regulates isolated phytocannabinoids under the Cannabis Act. Rules differ by product class and move often, so confirm the current national position before relying on this. Dated 2026-07-11; general information, not legal advice.
None has been established. CBL is among the least-studied cannabinoids, with no verified human or preclinical evidence for any benefit. What gets claimed for it comes from marketing or folklore, remains unproven, and CBG Atlas does not affirm it (not medical advice). Catalogue in progress.
Mostly as a trace marker of aged cannabis and as a reference compound that interests researchers. CBL is not an established ingredient or therapeutic, and wellness positioning for it lacks support (not medical advice). Catalogue in progress.
None has been verified. We have catalogued no confirmed pharmacology for CBL, whether receptor, enzyme or clinical. Old folklore sometimes credits CBL with the sedation attributed to "aged cannabis," but that link is unproven (not medical advice). Catalogue in progress.
None that we know of. No human studies of CBL are known, and the preclinical pharmacology is almost as thin, which puts CBL among the most under-researched cannabinoids. Every effect statement about it therefore stays catalogue in progress.
Nobody knows yet. CBL's safety is not established: no human safety studies, defined dose or long-term data. "Not known to be intoxicating" and "safe" answer different questions. Consult a qualified professional before use (not medical advice). Catalogue in progress.
They are unknown. No controlled study has documented adverse effects of CBL, and an empty file is a different thing from a clean bill of health. Products may also contain other cannabinoids or contaminants. If you feel unwell, stop and get advice (not medical advice). Catalogue in progress.
Nobody can say. Neither a safe nor an effective CBL dose has been established, and overdose data are absent, so the evidence gives "too much" no definition. As with any unstudied compound, more isn't better. Catalogue in progress. This is not dosing or medical advice.
Nobody knows, because no one has studied CBL interactions, in people or in the lab. Cannabinoids as a class can affect drug-metabolising enzymes, which makes an interaction plausible, though for CBL it remains unverified. If you take any medication, ask a clinician or pharmacist first. Catalogue in progress. (Not medical advice.)
Probably not. Standard drug tests look for THC's metabolite (THC-COOH), and CBL is neither THC nor a precursor of it, so direct interference is unlikely. The variable that matters is trace THC in a hemp or aged-cannabis product. Cross-reactivity data specific to CBL are essentially nonexistent, so a current third-party certificate of analysis is the only way to see what a product contains.
No. CBL forms from CBC rather than from THC, and pure CBL is THC-free. Products that contain it, often aged or full-spectrum material, may carry trace Δ⁹-THC, so check the certificate of analysis (COA) for the actual THC content.
Unlikely to be the direct cause, since tests are built to find THC and CBL is a different molecule. The risk is trace THC in the product. If you are drug-tested, choose products whose COA shows non-detectable THC.
Rarely on its own. CBL usually turns up as a trace component of aged or full-spectrum extracts, or as a reference isolate. Formats would follow other cannabinoids, such as oils or capsules, but CBL has no studied route, dose or effect (not medical advice).
Dedicated CBL products barely exist. CBL appears mainly as a minor constituent of broad- and full-spectrum hemp extracts and as an analytical reference standard for labs. The amounts are tiny and variable, so any product claim about CBL should come with a third-party certificate of analysis (COA) to back it.
No dose has been established. Without a study that defines a safe or effective amount, CBG Atlas offers no dosing guidance, and the number on a label is the manufacturer's choice rather than evidence. Consult a qualified professional (not medical or dosing advice). Catalogue in progress.
Nobody knows. CBL's onset and duration have never been studied, and it has no verified effect to time in the first place. Without CBL pharmacokinetic data, any timing claim is speculation (not medical advice). Catalogue in progress.
CBC is the parent, and CBL is what CBC slowly becomes under light or heat through a photochemical ring-closing reaction. So CBL is a degradation product of CBC rather than a sibling the plant makes on its own. Neither intoxicates, and CBC has more research behind it than CBL.
Both are products of age, from different parents: CBL forms from CBC under light, and CBN forms from THC by oxidation. Both build up in old cannabis and neither is intoxicating in the ordinary sense. Their evidence parts company sharply. CBN has in vitro data and three human sleep trials behind it, while CBL has essentially no verified pharmacology. Catalogue in progress for CBL.
They share little, in structure or in evidence. CBD is widely studied and has an approved prescription medicine for specific rare seizure disorders. CBL is a rare breakdown product of CBC with almost no research behind it, so any comparison of their effects would be guesswork on one side. Catalogue in progress.
Not in any way that can be verified. Structurally, CBL forms a tetracyclic class of its own, derived from CBC. Its pharmacology is unstudied, which leaves nothing to compare its effects against. The closest parallel is CBN, and only because both are aging and degradation products, a shared origin rather than shared activity.
CBL's molecular formula is C21H30O2 (molecular weight ≈ 314.46 g/mol), CAS 21366-63-2, PubChem CID 30607. The molecule is tetracyclic, formed when light closes a ring inside CBC, which makes it an isomer of CBC rather than a new skeleton. That chemistry is Established; CBL's pharmacology is not, and it stays catalogue in progress.
By photocyclization. Ultraviolet light drives a [2+2] cycloaddition in CBC that closes a new ring and creates CBL, and heat and time also contribute. Labs can make CBL by irradiating CBC on purpose; in nature it accumulates as cannabis ages.
Yes. CBL is a degradation product of CBC, produced over time by light and heat rather than by any plant enzyme. That origin defines CBL, and it parallels the way CBN forms as THC ages and oxidizes.
Yes. CBLA (cannabicyclolic acid) is described as the matching acid, and it is itself a photochemical product of CBCA, the acid form of CBC. Like CBL, CBLA is extremely rare and essentially unstudied, and we have catalogued no verified pharmacology for it. Catalogue in progress.
Mostly from lab suppliers, as an analytical reference standard. Beyond that it shows up as a trace component of aged or full-spectrum extracts, and as a consumer product it is very hard to find. CBG Atlas endorses no vendor. If you buy, insist on third-party lab results.
Because it forms slowly, from a parent that is scarce to begin with. CBL comes from CBC under light and heat, and CBC is itself a fairly minor cannabinoid, so CBL is present only in trace amounts (typically well under 0.1%). Isolating meaningful quantities is difficult and low-yield, which makes standalone CBL exceptionally scarce.
Ask for a certificate of analysis (COA) from an accredited third-party lab; for a compound this rare and unstudied, it matters more than usual. The COA should confirm any claimed CBL content, report the THC level and show contaminant screening. Be wary of any product claiming high CBL content until a COA confirms it.
There is little basis for recommending it. CBL has no established benefit and almost no research of any kind, so any value it has is speculative. Catalogue in progress. If you are curious anyway, treat it as an experiment, insist on current lab testing, and expect little. (Not medical advice.)
A third-party COA that actually verifies CBL content, since many claims go unverified, plus a compliant, declared THC level, contaminant screening and accurate labeling. Be especially skeptical of effect claims, "sedation" included, because none has been verified for CBL (not medical advice). Testing and transparency matter most.
Informational only, not medical advice. CBG Atlas is a scientific reference. Nothing here diagnoses, treats, cures or prevents any disease. Every claim on the page carries the grade of the evidence behind it, and the grade sets the words the claim may use. How we grade evidence.
Educational, not medical or legal advice. Statements about effects, benefits or uses report claims made by third parties. CBG Atlas does not make, adopt or affirm them. Legal status depends on jurisdiction, product class and date, and it changes, so check it against the official source. See how we grade and the safety page.
Cardiovascular note. CBG is a potent α2-adrenoceptor agonist in vitro, and α2 agonism can lower blood pressure. Anyone taking blood-pressure or other cardiovascular medication should consult a clinician before use. This is educational information, not medical advice.
Funding and independence. Peregrine Biopharma funds the platform and holds no editorial authority.
Report a safety event →Families
Its acid or neutral form
Head-to-head